2017 AACR Annual Meeting

Presentations:
Sunday, April 2
2:00 pm – 4:00 pm
Location: AACRcentral (Booth 1125) - WICR Resource Center - Lower Level Washington Convention Center
Women in Cancer Research Council Meet and Greet
Chairperson: Patricia LoRusso

Sunday, April 2
Minisymposium
3:00 pm – 5:00 pm
Location: Room 151, Level 1
Phenotypic analysis of single-cell breast cancer inhibition data reveals insights into EMT
William S. Chen, Smita Krishnaswamy

Sunday, April 2
Town Hall Meeting and Reception
6:00 - 8:00 PM
Location: Independence Ballroom A-D - Meeting Level 4 Marriott Marquis
Overview of Mouse Models
Marcus W. Bosenberg

Monday, April 3
Late-Breaking Minisymposium
8:00 am – noon
Location: Section 12
Oncometabolites induce a BRCAness state that can be exploited by PARP inhibitors
Samantha A. Streicher, Andrew T. DeWan, Hongyu Zhao, Harvey A. Risch

Tuesday, April 4
Lectureship
3:00 pm
Location: Room 202, Level 2
PROTACs: Targeted Protein Degradation as a Therapeutic Strategy
Craig Crews
Tuesday, April 4
Late-Breaking Minisymposium
3:00 pm - 5:00 pm
**Location:** Room 147, Level 1
*Oncometabolites induce a BRCAness state that can be exploited by PARP inhibitors*
Parker Sulkowski, Christopher Corso, Nathaniel Robinson, Susan Scanlon, Karin Purshouse, Yanfeng Liu, Ranjini Sundaram, Denise Hegan, Nathan Fons, Gregory Breuer, Yuanbin Song, Ketu Mishra1 Henk De Feyter, Robin de Graaf, Yulia Surovtseva, Stephanie Halene, Murat Gunel, Peter Glazer, Ranjit S. Bindra

**Workshops:**
**Saturday, April 1**
8:30 am – 8:50 am
**Location:** Ballroom C - Level 3 Washington Convention Center
*Next-generation pathology: Quantitative immunofluorescence and imaging mass cytometry*
Presenter: Kurt Schalper

Saturday, April 1
1:00 pm – 3:00pm
**Location:** Ballroom A-B - Level 3 Washington Convention Center
*Rationale and Design of Immune Checkpoint Combination Therapy*
Chair: Roy S. Herbst

Saturday, April 1
1:30 pm – 1:50pm
**Location:** Ballroom C - Level 3 Washington Convention Center
*Interrogating immune environment within tumor tissue*
Presenter: Kavita Dhodapkar

Saturday, April 1
2:05 pm – 2:55 pm
**Location:** Independence Ballroom B-E - Level 5B Grand Hyatt Washington
*WICR Professional Advancement Session: Intentional Yes and Graceful No-- How to Take Charge of Your Career*
Mentor: Patricia LoRusso

Sunday, April 2
2:05 pm – 2:30 pm
**Location:** Room 147 - Level 1 Washington Convention Center
*Smoking and lung cancer: Implications for pathogenesis, prevention, and treatment*
Presenter: Roy S. Herbst

Sunday, April 2
3:00 pm – 5:00 pm
**Location:** Room 145 - Level 1
*Laboratory and Computational Tools to Enhance Clinical Decision Making*
Chairperson: Joseph Paul Eder
Sunday, April 2
3:00 pm – 5:00 pm
Location: East Salon C - Level 1
Cancer Survivorship and Quality of Life
Chair: Tara Sanft

Sunday, April 2
4:53 pm – 5:03 pm
Location: Hall D-E - Level 2
Immuno-oncology Biomarkers in Clinical Trials
Discussant: Mario Sznol

Monday, April 3
4:05 pm – 4:20 pm
Location: Ballroom C - Level 3
Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors
Presenter: Scott Gettinger

Wednesday, April 5
10:45 am – 11:10 am
Location: Room 147 - Level 1
Inflammation and cancer: The role of exercise
Presenter: Melinda Irwin

Poster Sessions:
Sunday, April 2
1:00 pm - 5:00 pm
Location: Section 41
Live-imaging reveals the correction of skin deformities within two tumor-associated mutational models
Cristiana Pineda, Samara Brown, Valentina Greco

Location: Section 40
The Pi3K/Akt pathway mediates epithelial-mesenchymal transition (EMT) and malignant progression in BRCA-defective epithelial ovarian cancer
Mehida Alexandre, Z Ping Lin, Elena S. Ratner.

Location: Section 2
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan Black, Gary Altwerger, Alice Masserdotti, Francesca Pettinella, Luca Zammataro, Natalia Buza, Pei Hui, Elena Ratner, Babak Litkouhi, Dan-Arin Silasi, Masoud Azodi, Peter Schwartz, Alessandro D. Santin
Monday, April 3
8:00 am - 12:00 noon

Location: Section 27
Multiplexed analysis of fixed tumor tissues using imaging mass cytometry
Parker Sulkowski, Christopher Corso, Nathaniel Robinson, Susan Scanlon, Karin Purshouse, Yanfeng Liu, Ranjini Sundaram, Denise Hegan, Nathan Fons, Gregory Breuer, Yuanbin Song, Ketu Mishra, Henk De Feyter, Robin de Graaf, Yulia Surovtseva, Maureen Stephanie Halene, Murat Gunel, Peter Glazer, Ranjit S. Bindra

Location: Section 43
Oncometabolites induce a BRCAness state that can be exploited by PARP inhibitors
Roslyn Tedja, Ayesha B. Alvero, Carlos Cardenas, Mary Pitruzzello, Yang Yang-Hartwich, Cai Roberts, Gil G. Mor

Location: Section 4
Evaluation of GABRP as a novel therapeutic target in triple negative breast cancer
Vikram B. Wali, Gauri A. Patwardhan, Christos Hatzis, Lajos Pusztai

Location: Section 44
The omentum promotes ovarian cancer cell survival by increasing cell cycle duration and chemoresistance
Carlos Cardenas, Ayesha B. Alvero, Mary Pitruzzello, Roslyn Tedja, Gil G. Mor

Location: Section 32
A gene expression-based nomogram predicts overall and progression free survival in PRRT-treated gastroenteropancreatic neuroendocrine tumors
Irvin M. Modlin

Monday, April 3
1:00 - 5:00 PM

Location: Section 19
RAD51 and AICDA define a new synthetic lethal interaction that is targetable in multiple tumor types
Patrick Sung

Location: Section 3
A systematic investigation of the effect of scheduling of targeted combination therapies on response and dynamics of relapse in triple negative breast cancer cells

Location: Section 19
Homologous Recombination and DNA Double-Strand Break Repair
Susan E. Scanlon, Parker L. Sulkowski, Peter M. Glazer

Location: Section 19
Inhibition of RAD51 with a cell penetrating antibody, 3E10
Peter M. Glazer, Audrey Turchick
**Location:** Section 19  
DNA polymerase beta participates in DNA end-joining  
Sreerupa Ray, Michelle DeVeaux, Gregory Breuer, Ranjit Bindra, Daniel Zelterman, Joann Sweasy

**Tuesday, April 4**  
8:00 am - 12:00 noon  
**Location:** Section 5  
Mechanism based quality control (MBQC) for the four-herb Chinese medicine formulation, PHY906(YIV-906) and other herbal products  
Wing Lam, Yongshen Ren, Fulan Guan, Zaoli Jiang, William Cheng, YungChi Cheng

**Location:** Section 34  
Genetic variations in the AGER pathway and risk of pancreatic cancer  
Guochong Jia

**Location:** Section 32  
Validation of novel high-plex protein spatial profiling quantitation based on NanoString's Digital Spatial Profiling (DSP) technology with quantitative fluorescence (QIF)  
Maria I. Toki, Daniel E. Carvajal-Hausdorf, Yalai Bai, David L. Rimm

**Location:** Section 31  
Analysis of KRAS variant in a cohort of resected HPV negative HNSCC  
Jeffrey Mufson

**Location:** Section 34  
Genetic variations in the AGER pathway and risk of pancreatic cancer  
Guochong Jia

**Wednesday, April 5**  
8:00 am - 12:00 noon  
**Location:** Section 24  
PHY906(YIV-906), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Immune checkpoint blockade therapy: anti-PDL1, anti-PD1, anti-PD1/CTLA4 against melanoma  
Wing Lam, Zaoli jiang, Xue Han, Lieping Chen2, YungChi Cheng

**Location:** Section 13  
Nutrition and Anthropometric Features  
Leah M. Ferrucci, Brenda Cartmel, Maura Harrigan, Tara Sanft, Caroline H. Johnson, Lajos Pusztai, Anees B. Chagpar, Melinda L. Irwin

**Location:** Section 24  
Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC)  
Ila J Datar
Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC)
Franz Villarroel-Espindola, Ila J. Datar, David L. Rimm, Roy S. Herbst, Kurt A. Schalper